회사 개요
Aytu BioPharma, Inc. (AYTU) is a pharmaceutical enterprise dedicated to the commercialization of novel therapeutics for markets in both the United States and internationally. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized medical treatments rather than broad-market commodity drugs. This business model is supported by a workforce of 82 employees and a total market capitalization of $27.48M, alongside annual revenue (TTM) of $62.64M. These valuation and revenue figures indicate that the company maintains a small-cap profile with a relatively modest revenue stream, positioning it as a specialized player rather than a dominant market leader in the broader pharmaceutical landscape.
재무 건전성
The company reported revenue of $62.64M over the trailing twelve months, yet it recorded a net income of -$24,559,000 and an EBITDA of $4.03M. The substantial gap between the positive revenue figure and the negative net income reveals a significant cost structure burden, where operating expenses and other costs exceed gross profits by a wide margin, resulting in a net loss despite generating cash from operations. Free cash flow stands at -$6,978,375, which indicates that the company is currently consuming cash reserves rather than generating surplus liquidity for reinvestment or debt reduction. This negative cash flow trajectory suggests limited financial flexibility in the short term, relying heavily on existing cash balances to fund operations. Regarding profitability margins, the gross margin is 66.8%, indicating a healthy pricing power or low cost of goods sold relative to sales; however, the operating margin is -13.0% and the profit margin is -39.0%, reflecting high overhead costs that erode earnings before and after interest and taxes. The balance sheet shows a cash position of $30.02M against total debt of $22.10M, while the debt-to-equity ratio is 155.63, suggesting a leveraged structure where liabilities significantly outweigh equity. Despite the leverage, the current ratio of 1.16 indicates that the company possesses sufficient current assets to cover its current liabilities, though the buffer is tight. Return on Equity is -109.2% and Return on Assets is -0.2%, metrics that reveal that management has not yet generated positive returns on the capital employed due to persistent net losses.
밸류에이션 평가
Valuation metrics for Aytu BioPharma show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is 15.06, implying that the market prices the stock based on anticipated future earnings recovery rather than historical performance. The price-to-book ratio is 1.93, which indicates that the market values the company at nearly twice its book value, suggesting an expectation of intangible asset value or future growth potential despite current losses. Alternative valuation multiples such as the price-to-sales ratio of 0.44 and an EV/EBITDA of 4.86 provide context for the stock's relative cheapness compared to peers, though these metrics must be interpreted with caution given the negative earnings profile. The 52-week trading range spans from a low of $0.96 to a high of $3.07, and based on the forward P/E context and recent market data, the current share price sits within this established historical volatility range. The stock exhibits a beta of 0.28, which signifies that the stock's price volatility is substantially lower than the broader market, making it a low-beta security that moves less aggressively than the general equity market.
Growth & Income
Revenue growth year-over-year stands at -6.5%, while earnings growth is N/A due to the company's current net loss status, indicating that the company is contracting in terms of top-line sales rather than expanding. Because the company is not generating positive net income, it does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its remaining resources into research, development, and commercialization efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by revenue contraction and a lack of current income generation, reflecting a phase where capital is being deployed to achieve profitability rather than returning value through dividends or earnings expansion.